Logo

ARVN

Arvinas, Inc.

ARVN

Arvinas, Inc. • NASDAQ
$12.57 ▲ 1.21% (+0.15)
Market Cap $913.15 M
52w High $27.00
52w Low $5.90
Dividend Yield 0%
P/E -15.52
Volume 631.24K
Outstanding Shares 72.64M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $41.9M ▲ $85.7M ▼ $-35.1M ▲ -83.771% ▲ $-0.48 ▲ $-34M ▲
Q2-2025 $22.4M ▼ $93.9M ▼ $-61.2M ▼ -273.214% ▼ $-0.84 ▼ $-70.1M ▼
Q1-2025 $188.8M ▲ $117.4M $82.9M ▲ 43.909% ▲ $1.14 ▲ $72.7M ▲
Q4-2024 $59.2M ▼ $117.4M ▼ $-45.1M ▲ -76.182% ▼ $-0.63 ▲ $-56.6M ▲
Q3-2024 $102.4M $162.7M $-49.2M -48.047% $-0.68 $-59.2M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $787.6M ▼ $844.3M ▼ $279.9M ▼ $564.4M ▼
Q2-2025 $861.2M ▼ $909.3M ▼ $300M ▼ $609.3M ▼
Q1-2025 $954.3M ▼ $1.001B ▼ $341M ▼ $660.1M ▲
Q4-2024 $1.039B ▼ $1.091B ▼ $529.7M ▼ $561.7M ▼
Q3-2024 $1.122B $1.167B $581.1M $586M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-35.1M ▲ $-59.1M ▲ $63.5M ▼ $-17.8M ▼ $-13.4M ▼ $-59.2M ▲
Q2-2025 $-61.2M ▼ $-95.4M ▼ $128.8M ▲ $500K ▲ $33.9M ▲ $-96.6M ▼
Q1-2025 $82.9M ▲ $-88.9M ▼ $69.5M ▼ $-100K ▼ $-19.5M ▼ $-89.3M ▼
Q4-2024 $-45.1M ▲ $-84.1M ▲ $98.9M ▲ $500K ▼ $15.3M ▲ $-84.4M ▲
Q3-2024 $-49.2M $-128M $50.5M $2.4M $-75.1M $-128.7M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
License
License
 $0 ▲$130.00M ▲$130.00M ▲$130.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Arvinas remains a classic clinical‑stage biotech story: very modest revenue, all from collaborations rather than product sales, and sizable ongoing losses. The cost base is dominated by research and development and supporting infrastructure, which is typical at this stage. Losses widened as the pipeline expanded and then began to narrow more recently, suggesting some cost discipline or better collaboration economics. Gross margins are effectively perfect on paper because there is no commercial manufacturing yet; the real pressure is below the revenue line in R&D and overhead. Overall, the income statement shows high investment in science today with no recurring commercial revenue to offset it yet.

Balance Sheet

Balance Sheet The balance sheet shows a company that has been well-capitalized historically, with a solid asset base and very little financial debt. Equity has been gradually eroded by repeated annual losses, which is expected for a company funding drug development from the balance sheet. Cash and equivalents have moved down from earlier peaks, but total assets remain significant, likely reflecting marketable securities and collaboration-related assets. The minimal use of borrowing reduces financial risk but increases reliance on equity funding and partnership cash to sustain operations. The balance sheet is still supportive of near‑term development plans, but prolonged delays or setbacks could strain it over time.

Cash Flow

Cash Flow Arvinas is consistently burning cash in its core operations, reflecting heavy R&D spending and no product cash inflows yet. One standout year of positive operating cash flow appears tied to large one‑time payments, likely from partnerships, rather than ongoing commercial activity. Free cash flow tracks closely with operating cash flow because capital spending needs are quite low, so cash usage is almost entirely driven by research and corporate expenses. This pattern means future cash health will depend heavily on additional partnership payments, potential new financings, or eventual product approvals rather than internal cash generation in the near term. The current trajectory is normal for a clinical‑stage biotech but leaves limited margin for prolonged setbacks without fresh capital.

Competitive Edge

Competitive Edge Arvinas holds a clear early‑mover position in targeted protein degradation, with one of the first and most mature PROTAC platforms in the industry. Its scientific heritage, broad patent estate, and years of specialized know‑how create real barriers for newer entrants. High‑profile collaborations with large pharmaceutical partners validate the technology and help extend its reach, though changes in partnership structures (such as Pfizer stepping back from co‑commercialization) highlight that strategic relationships can shift over time. The field is drawing more competitors, including large and well‑funded players, which raises the bar for differentiation on safety, efficacy, and convenience. Overall, Arvinas is a leading name in a promising niche, but must keep executing clinically and strategically to maintain that edge as the landscape fills in.

Innovation and R&D

Innovation and R&D Innovation is the core of Arvinas’ identity: it is pioneering drugs that destroy disease‑causing proteins rather than just blocking them. Its platform targets proteins long considered “undruggable,” and early work suggests the potential for oral drugs that reach both tumors and the brain, opening oncology and neurology opportunities. The pipeline spans breast and prostate cancer, blood cancers, Parkinson’s disease, and tough oncogenic drivers like KRAS, giving the company multiple scientific shots on goal. Heavy R&D spending reflects this ambition and is the main reason for persistent losses, but it also builds a broad data and know‑how advantage that may be hard for rivals to quickly copy. The key uncertainty is clinical: several upcoming readouts and regulatory milestones will reveal how much of the platform’s theoretical promise translates into real‑world benefit and sustainable value.

Summary

Arvinas is a research‑driven biotech with a strong scientific story and a weak but typical financial profile for its stage. The company has no product revenue yet and continues to post substantial losses, financed largely through past capital raises and partnership deals. Its balance sheet is relatively clean, with low debt and a still‑meaningful cash and asset base, but ongoing cash burn means it remains sensitive to clinical outcomes, deal flow, and market conditions. Competitively, Arvinas stands out as an early leader in targeted protein degradation, supported by deep expertise, a significant patent portfolio, and validation from major pharmaceutical partners, even as the space grows more crowded. The next few years will likely be defined by regulatory decisions on its lead program and key data readouts across the pipeline, which will determine whether its scientific edge can evolve into a durable commercial franchise strong enough to reshape its financial picture.

NEWS

November 26, 2025 · 7:00 AM UTC

Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference

Read more

November 24, 2025 · 7:00 AM UTC

Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)

Read more

November 5, 2025 · 7:00 AM UTC

Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Read more

November 3, 2025 · 4:00 PM UTC

Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting

Read more

November 3, 2025 · 7:00 AM UTC

Arvinas to Participate in Upcoming Investor Conferences

Read more